



1635
7c
\$

ATTORNEY'S DOCKET NO: C1037/7017 (HCL/MAT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant: Robert L. Bratzler and Deanna M. Petersen
Serial No: 09/800,266
Conf. No: 3753
Filed: March 5, 2001
For: IMMUNOSTIMULATORY NUCLEIC ACIDS AND CANCER
MEDICAMENT COMBINATION THERAPY FOR THE TREATMENT
OF CANCER
Examiner: Jon E. Angell
Art Unit: 1635

COPY OF PAPERS
ORIGINALLY FILED

RECEIVED
JUN 11 2002
TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on May 22, 2002.


Maria A. Trevisan, Reg. No. 48,207

Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL


Transmitted herewith are the following documents:

- ☒ Response to Restriction Requirement
- ☒ Check in the amount of \$110.00 (one month extension, large entity)
- ☒ Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 720-3500, Boston, Massachusetts.

If any additional fee is determined to be due by the Examiner, the Examiner is authorized to charged the appropriate fee to the account of the undersigned, Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully Submitted,



Maria A. Trevisan, Reg. No. 48,207
Wolf, Greenfield & Sacks, P.C.
Federal Reserve Plaza, 600 Atlantic Avenue
Boston, MA 02210-2211
Attorney for Applicants

Docket No. C1037/7017 (HCL/MAT)
Date: May 22, 2002
X06/09/02

615062.1



COPIES OF PAPERS
ORIGINALLY FILED

#9
KP
6-18-02

ATTORNEY'S DOCKET NO: C1037/7017 (HCL/MAT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Robert L. Bratzler and Deanna M. Petersen
Serial No: 09/800,266
Conf. No: 3753
Filed: March 5, 2001
For: IMMUNOSTIMULATORY NUCLEIC ACIDS AND CANCER
MEDICAMENT COMBINATION THERAPY FOR THE TREATMENT
OF CANCER
Examiner: Jon E. Angell
Art Unit: 1635


RECEIVED

JUN 11 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on May 22, 2002.


Maria A. Trevisan, Reg. No. 48,207

Commissioner for Patents
Washington, D.C. 20231

Response to Restriction Requirement

Sir:

In response to the Restriction Requirement mailed from the United States Patent and Trademark Office on April 9, 2002, Applicants hereby request entry of the following election. A one month extension of time is respectfully requested and the appropriate fee is submitted herewith.

Election

Applicants hereby elect Group I (claims 1-17 and 31).

Applicants further elect

- a) a chemotherapeutic agent that is Paxex/Paclitaxel;
- b) an immunotherapeutic agent that is Herceptin;
- c) a cancer vaccine that is Her2/neu; and
- d) a hormone therapy that is estrogens.

Applicants wish to clarify that Group I drawn to a method of cancer treatment/prevention using a nucleic acid embraces claims 1-17 and 31. The Examiner listed claims 1-12 and 31 and omitted claims

615062.1

06/10/2002 MBERHE 00000035 09800266

01 FC:115

110.00 DP